The review was recommended to Council by its Standards Committee following its exploration of the implications of new technologies for both animal health and welfare and veterinary regulation.
The main areas under consideration are the interpretation and application of an animal being under the care of a veterinary surgeon, and the provision of 24-hour emergency cover.
The College says that during the course of its research, which included numerous meetings and reports, a public consultation and examination of external legal advice, the Committee identified a number of anomalies in the College’s existing guidance that could affect how the Code’s provisions were applied across a range of different scenarios.
Chair of the Standards Committee, Dr Kate Richards, said: "It became clear to us that we could not consider telemedicine and remote prescribing in isolation and that it raised broader questions around the appropriateness of, and justification for, certain elements of existing RCVS guidance. I’m therefore pleased that RCVS Council has decided that the right and responsible approach is first to conduct a full review of these provisions."
The College anticipates that the review will require wide engagement from all relevant sectors, potentially including a Select Committee-style hearing in certain areas. This, it says, would help to ensure any decision to treat different groups differently, in relation to 'under care' and 'out-of-hours', is both reasoned and justified.
In the meantime, the College says that the current provisions of the RCVS Code of Professional Conduct and its supporting guidance remain in full effect.
Further information about the review will be made available in due course.
UPDATE (19/06/2019)
Following a number of concerns raised by members of the profession about this story, the RCVS has issued a further statement as follows:
We would like to acknowledge and address a number of concerns that have arisen amongst the profession following RCVS Council’s discussion last week that followed up queries raised during the previous debate in November, around the provision of telemedicine services, including remote prescribing.
The RCVS Council decision, made unanimously, was to proceed with a wide-ranging review of RCVS supporting guidance concerning 24-hour emergency cover and the interpretation and application of ‘under veterinary care’, and to postpone the proposed telemedicine trial for the foreseeable future and certainly until the conclusion of this review. The review will encompass, but not be limited to, consideration of what restrictions or safeguards to place on remote prescribing in the form of vet-to-client telemedicine.
RCVS Council discussed this paper ‘in committee’ in order to be able to examine the confidential legal advice it had requested at its previous meeting. The decision to hold these discussions privately was purely related to the privileged nature of legal advice and in no way related to any ‘commercial interests’.
We recognise fully that this is a complex issue, with strong views held on all sides. However, it is entirely right and proper for RCVS Council members to be able to discuss and debate such topics in detail, before reaching a decision through a vote. In the course of such discussions, issues may arise that had not previously been identified, and which may alter the original direction of thinking.
We appreciate that Council’s decision was perhaps unexpected, especially as the original topic had been under consideration for some time. This is why we announced it as soon as possible, along with an indication of what Council would like to happen next.
Whilst it is far too early to have worked out the details of the agreed review, it will be open and inclusive in parallel with our previous consultations, which continue to receive considerable levels of engagement across the veterinary professions and wider industry stakeholders.
We will publish full details about our plans for this review over the coming weeks, and will continue to work hard to engage all veterinary professionals in these important decisions.
Veteran campaigner and RCVS Councillor Danny Chambers MRCVS (pictured right) has started a petition to George Eustice on change.org that: Future trade deals must not compromise animal welfare and public health.
The petition has gathered an impressive 21,984 signatures, of which Danny says that more than 500 are from veterinary surgeons.
Meanwhile VetPartners is calling on the retail and food service sector to give priority to British produce, even if future trade deals enable the import of foods produced to lower standards.
Ian Cure, farm director at VetPartners, is contacting the UK’s main retailers to discuss how they can support British farmers in the months and years to come. He has the backing of the clinical directors at each of the 28 farm or mixed practices within the group, which collectively look after the health and welfare of over 30% of the UK’s dairy population and 45% of the pig population.
“We are asking retailers to prioritise a range of Red Tractor certified produce at varying prices, while avoiding designating shelf space to imports of a lower quality. Likewise, the food service sector can choose to source from UK food supply chains.
“These sectors have a high level of influence, as consumers will pick from what is clearly available, which is why we see it as the best way to support our farmers.
“We are incredibly concerned about how the higher welfare and production standards in UK agriculture will be protected long term, given that MPs failed to enshrine that protection in law when voting against the recent amendment to the Agriculture Bill last month.
“Future trade deals to allow the import of cheap food from countries outside of the EU would be a step in the wrong direction, as our farmers will not be competing on an even playing field as they attempt to compete with countries with lower costs of production.”
However, Ian adds that this is not just a welfare issue: "If the UK livestock sector is forced to adopt practices that are frowned upon in Europe to compete, such as the American applications of hormone growth treatments and chlorinated chicken, we would be severely risking our local, lucrative European export market.
“While trade with countries such as the USA and Australia may have benefits from an economical perspective, the carbon emissions associated with longer distance transport of food is a real concern.
“We see it as imperative that higher welfare standards are maintained, while reducing the carbon footprint of our food supply – it's the right, sustainable thing to do. As MPs have let down the sector, we are now calling on retailers and the food service industry to back UK farming."
The Disciplinary Committee heard that Mrs Garfield had told a representative of the Retired Greyhound Trust (RGT) that she had possession of a greyhound called Lola, that she proposed keeping Lola living with her as an adoptee, and that she would not relinquish possession of Lola except to the RGT. This was despite the fact that, at the time of signing the adoption agreement, she had already given Lola to another charity named Greyhound Gap and that, as a result, her conduct was misleading and dishonest.
In considering the facts of the case, the Committee found the charges and all constituent parts proven and went on to consider whether this amounted to disgraceful conduct in a professional respect.
Judith Way, chairing the Committee and speaking on its behalf, said: "The end result of the respondent’s decisions and conduct meant that RGT was persuaded to pass lawful possession and ownership of the dog Lola to the respondent when it would not have agreed to do so had it been told the truth by her.
"In truth, the respondent was not going to adopt and re-home Lola herself. Instead the respondent’s plan and intention was that Lola should be passed on to a third party who had been recommended by a rival dog rescue charity for rehome and adoption."
Judith added: "The consequence was that a social media dispute broke out when the rival dog charity decided to attempt to take advantage of the erroneous belief of the respondent that a decision had been taken by RGT to put Lola to sleep. The publicity generated by the respondent’s erroneous belief… was obviously adverse…. The gravamen [seriousness] of the respondent’s dishonest conduct was that she set one dog rescue charity against another, caused them to spend publicly raised funds on a legal dispute about who should be allowed to retain Lola when those precious funds ought, instead, to have been spent on their charitable objectives."
The Committee judged that the charge and its parts constituted serious professional misconduct and went on to consider the sanction against Mrs Garfield.
In considering the proportionate sanction the Committee took into account both mitigating and aggravating factors. In terms of aggravating factors the Committee considered that the dishonesty was pre-meditated, that she accused members of a rescue charity of lying and demonstrated no or only minimal insight into her wrongdoing. In mitigation the Committee considered that Mrs Garfield had cooperated with the College in its investigations, that she had acted in the genuine belief that she was acting in the best interests of Lola and that her conduct did not put Lola at risk or cause her to suffer any adverse consequences as a result. The Committee also accepted the testimonials and positive evidence from colleagues.
However, the Committee decided that removal from the Register would be the only appropriate sanction.
Summing up Judith Way said: "The reputational consequences for RGT were potentially significant bearing in mind that it is a rescue organisation with some 57 or so branches across the country. All of these consequences, actual and potential, stem from the respondent’s premeditated act of dishonesty in relation to which the Committee considers she showed very limited insight prior to this disciplinary hearing, as she did during the course of this hearing.
"In the result, it is the conclusion and decision of this Committee that the only proper sanction that can be imposed in this case is that the respondent’s name should be removed from the Register.”
Mrs Garfield has 28 days from being informed of the Committee’s decision to appeal.
Having had a three-month sabbatical working at Fitzpatrick, Jonathan decided to relocate from New Zealand where most recently he'd been Head of the Companion Animal Group at Massey University.
Jonathan said: "My prime passion is working directly with animals and their families in a supportive and exceptional clinical setting. I enjoy pushing boundaries and not accepting the status quo. I want to identify better ways of improving outcomes for patients, and minimising the impact of the disease (or its treatment) on an animal’s quality of life. My sabbatical at Fitzpatrick Referrals exposed me to their tremendous energy and real passion for patient and client care. From the moment the clients walk in the door, I feel there is an embrace that lets people know we truly care and want to do the best for their animal friend. I am looking forward to discovering what we can achieve together. Cancer management is such an important opportunity, with the power to change both animal and human lives positively. The direction and focus of Fitzpatrick Referrals in this area is already incredibly exciting.”
Clinical Director of Oncology and Soft Tissue, Professor Nick Bacon said: "On Jon’s first day of his sabbatical, he jumped right into the team and made an immediate positive impact. He hasn’t looked back. He carries with him such a good energy, which we all absorb and hopefully reflect back. His knowledge of implant design for dealing with defects in the mandible and elsewhere is exceptional and I am looking forward to watching that develop. I am also very pleased that Jon’s wife Sharyn is able to join the team; she is very experienced in the field of advanced imaging in humans, including Fluoroscopy and PET-CT. This is already benefitting our patients as we improve our diagnostic and treatment abilities, and get ready for the future."
Jonathan has active research interests in several clinical areas including soft tissue sarcoma, injection-site sarcoma, endoprosthetics and haemangiosarcoma. He also supports the concept of One Medicine as his PhD research into soft tissue sarcoma, haemangiosarcoma and endoprosthetics has a potential relevance in improving the understanding of treatment paradigms for humans and animals.
The company says it recognises how frustrating it can be for veterinary surgeons if the owner doesn't recognise that their dog has a painful condition. This can be compounded by short consult times, leaving vets unable to fully communicate the implications and treatment options for the disease.
In the video, Zoe encourages vets to tailor their language to each case, in particular, using the language dog owners will use.
While undertaking her research Zoe noticed that many owners do not talk about OA in the same way that vets might; instead of referring to lameness or pain, many owners will refer to the actual physical signs of OA such as stiffness or communicate that their dog is slowing down.
Zoe has also warned that not all owners are convinced by visual demonstrations such as flexing and extending the dogs joints. Instead, she suggests encouraging the owner to get hands-on.
Zoe said: "Point out the visual changes suggestive of osteoarthritis that you can see, such as muscle loss, scuffed nails, and enlarged joints. And encourage them to have a look and a feel, comparing affected and unaffected joints. Hopefully, the owner may be more receptive to the conversation now they associate it with a symptom they can recognise."
Zoe says she also finds that many owners of older dogs often misinterpret the signs of OA as 'just old age' and may not be aware that the condition can be managed effectively with medication, the right exercise, diet and by making modifications in the home.
Elanco has also produced an OA management template which enables both the vet and the owner to create a tailored plan. It provides the owner with information to take away with them about how to modify their home, written in collaboration with Founder of Canine Arthritis Management, Hannah Capon.
Lastly, Zoe recommends a whole practice approach to becoming experts on OA, veterinary nurses in particular. She said: "Vet nurses often have great ideas about how to explain the condition in a way that owners understand. Better owner understanding of OA should lead to better adherence to treatment plans and ultimately better clinical outcomes."
To watch the video, click here.
To access the suite of assets Elanco has created for Onsior (which includes the management plan, social media posts for the practice, and infographic to help owners to spot the signs of OA) visit: www.myelanco.co.uk
The Prince's Trust 'creates life-changing opportunities' for those aged 11-30 and Nick has long-held a passion for making a difference to young lives. He has set up three charities for young people: with learning disabilities; who want to campaign to change the world; and who want to break down the barriers to enjoying nature and the outdoors.
Nick has led the RCVS since September 2012. During his tenure, developments at the College include a new Royal Charter, major governance reform, improved regulation of veterinary nurses, the instigation of Vet Futures, the introduction of the alternative dispute resolution service, significant evolution within the Practice Standards Scheme, the refocusing of RCVS Trust into RCVS Knowledge, the launch of Mind Matters, and the recognition of the College as a Great Place to Work.
Nick said: "It has been a great privilege to be CEO of the College and to work with such amazing staff, such a progressive Council and such a decent and caring profession. It is no surprise to me that vets and vet nurses are among the most trusted professionals in this country, and in my view this is due to their professionalism and to the excellence of the Royal College in maintaining and advancing standards. I hope I have played my part in helping the College and the profession navigate through a period of great change and preparation for significant change to come.
"At The Prince’s Trust I will be focused on the next generation, helping to give young people the confidence and purpose they need to make a success of their lives and the world around them. I know from my own personal experiences of school, and the various charities with which I have been involved, how many young people are not given the best chance in life. I cannot think of a better mission to take on."
RCVS President Chris Tufnell said: "I feel very fortunate to have worked closely with Nick over his five years with the RCVS; he has made a tremendous contribution to the College and our professions. With his energy and drive, he has infused the College with a culture of openness, engagement and dedication and has inspired the team through some impressive achievements.
"Nick’s leadership will enable vets and veterinary nurses to fulfil their potential and it's fitting that he's moving on to a role which benefits the lives of others. Meanwhile, there's a considerable amount of important work being done by the RCVS and I am confident that we have a strong team at Belgravia House to manage this until the new CEO is in post."
The RCVS says its Operational Board will be reflecting on Nick’s successes and the future needs of the College, before developing a specification for the new CEO and a recruitment process over the coming weeks.
Ceva says the new product is the fruit of research into the composition of the main feline pheromones which pass through the incisive ducts to the Vomeronasal Organ (VNO), which in turn led to the discovery of a new pheromone complex which 'provides an enhanced message of social confidence and safety in the cat’s environment by conveying more impactful messages to it'.
According to the company, Feliway Optimum helps cats with more signs of stress, in more situations and calms cats better than ever. The product is proven to help with more stress-related signs faster than existing pheromones, with all signs of stress showing continuous improvement until day 28 of use and are visible from day 71. These include scratching, urine spraying, multi-cat tensions and conflicts and changes and fears.
Feliway Optimum is available as a plug-in diffuser with 30-day refills.
Abigail King, senior behaviour product manager at Ceva Animal Health said: "We have led the way with research for over 20 years with Feliway Classic and Feliway Friends, but it is now time to go that step further.
"Feliway Optimum is an extremely exciting addition to the range which will help solve all common signs of stress to provide enhanced serenity in a household.
"Nearly 60 per cent of cats show visible signs of stress2 and Feliway Optimum will really help combat this with an over 70% reduction”.
There is a webinar about the new product, presented by Professor Patrick Pageat and Dr Andy Sparkes, which is available by emailing Ceva.
For more information, visit www.feliway.com/uk, call Ceva on 01494 781510 or email cevauk@ceva.com.
References
Chanelle's head of sales and marketing, Killian Gaffney said: "The total UK market is around 80,000 bottles annually. However, with the major supplier announcing some re-stocking in March but full availability still under question, there is a real sense of urgency for practitioners.
"The Chanelle team worked throughout December with our manufacturing division to ensure that the UK product shortfall could be alleviated.
"Air freighting supplies seemed the obvious course of action, and ensured we could supply the UK market as quickly as possible."
For further information, contact: Chanelle on 00353 91 841 788.
The recall is due to the fact that particulates have been found in identified batches of product during routine stability testing.
The affected batches are:
This issue only applies to the batches listed above. All other batches and the 20 ml pack size are not affected.
For further information regarding the recall, contact Richard Beckwith on 07584 099536 or: richard.beckwith@jurox.co.uk.
The company says it has made the test available in response to customer demand and growing evidence that in rare cases pets living with COVID-19-positive humans can be at risk of infection.
The test will be available to veterinary surgeons in North America this week and will roll out across most of the world in the coming weeks, via the company's worldwide network of laboratories.
Jay Mazelsky, President and Chief Executive Officer of Idexx Laboratories said: "We have continued to monitor the rapidly evolving public health crisis worldwide, paying special attention to the effects on pets.
"While there is currently no evidence that dogs or cats play a role in transmitting the disease to humans, it became clear offering the test was the right thing to do when we saw clinical evidence that pets—especially cats and ferrets—can in rare cases be at risk for infection. And, we heard from our customers around the globe that veterinarians needed a testing option."
Idexx recommends the test is used when three specific criteria are met:
Idexx says leading health authorities agree with the company that transmission of the SARS-CoV-2 virus is primarily person-to-person and advise against testing asymptomatic pets. Since mid-February, the company has tested over 5,000 specimens for the virus, from cats, dogs, and horses with respiratory symptoms in 17 countries. To date, it has found no positive results, suggesting that dogs and cats living with infected people generally remain uninfected, except in rare and isolated cases.
For information about the Idexx SARS-CoV-2 (COVID-19) RealPCR Test for pets, visit idexx.com/covid19-pet-test.
Novartis Animal Health UK has announced a strategic partnership with Procter & Gamble (P&G) Pet Care, maker of the Eukanuba and Iams brands.
As part of the arrangement, the Novartis sales team will start detailing P&G's pet nutrition products to veterinary practices from April 1, 2014 in the UK and at a later stage in Ireland.
Novartis says the partnership brings together two highly complementary portfolios: Novartis is a leader in pet health areas in which P&G's Eukanuba Veterinary Diets have acknowledged strong clinical formulations, specifically dermatology, nephrology, and orthopaedic conditions. The partnership is designed to offer veterinary surgeons a holistic and flexible portfolio in key canine and feline health areas, as well as increased commercial and technical support and partnership from the Novartis sales team.
Simon Harris, sales & marketing manager at Novartis said: "Novartis Animal Health already offers expertise in key companion animal diseases together with innovative veterinary medicines. Based on research done with veterinary customers, we believe nutrition also plays an important role in disease management in pets, making our strategic cooperation with P&G Pet Care a natural fit that offers real benefits to veterinarians and their patients."
Dr. Penny Watson, Senior Lecturer in Small Animal Medicine at the University of Cambridge, said: "Clinical nutrition plays a key role in patient management and is an important complement to medicine in order to achieve a successful outcome. This combination of Eukanuba Veterinary Diets and Novartis Animal Health products helps highlight the importance of dispensing clinical diets as part of a multi-modal approach to effective patient management. Additionally, high quality nutrition is also recommended by vets as part of a normal day-to-day healthy lifestyle."
The partnership will be launched at the BSAVA Congress. The two companies say they'll have a joint presence at the event to showcase the strength and versatility of the combined Novartis and P&G Pet Care portfolio to the veterinary community.
Animalcare has released further information about Vitofyllin (propentofylline), its new CNS stimulant for dogs.
According to the company, Vitofyllin helps restore vitality and willingness to exercise, especially in the senior dog, by improving peripheral and cerebral vascular blood circulation. It is indicated to help improve dullness, lethargy and overall demeanour in dogs. In addition it has a bronchodilatory activity equivalent to amilophylline (a salt of theophylline)
Animalcare says that with dogs living longer, age-related problems are on the increase. The company highlights the example of Cognitive Dysfunction Syndrome (CDS), a neurodegenerative disease that affects older dogs. CDS is characterised by various pathological processes with signs that include disorientation, changing interaction with people or other pets, sleep-wake cycle alterations, soiling in the house and decreased activity levels.
The company says these subtle behavioural changes are unlikely to be picked up at a routine annual check. Indeed, in one study 75% of owners of dogs aged over 7 reported at least one behavioural sign consistent with CDS, however only 12% reported their concerns to a vet.2
Vitofyllin is available in 50mg and 100mg strengths in blister packs containing 56 tablets. Presented as 'easy to administer' four-way split cross-snap-tabs which can be divided into halves or quarters to enable more accurate dosing to be achieved whatever the weight of animal, even down to 2.5kg bodyweight.
Vitofyllin is POM-V licensed and has a 3 year shelf-life. Waiting room posters and client leaflets are available to support recognition of behavioural signs by clients and practice staff.
Further iinformation, and details about a special launch offer are available from local Animalcare representatives.
Reference
Eurovet Animal Health has announced that it is bringing a veterinary licensed vitamin K1 (phytomenadione) injectable preparation to the UK.
Eurovet says the new preparation, available from the wholesalers by Monday at the latest, will ensure that the previous supply problems of vitamin K1, will be overcome.
According to the company, the intravenous route is the only route to ensure a 100% bioavailability of vitamin K1 almost immediately and in a crisis situation is the best route of treatment. During anticoagulant poisoning, the coagulation factors are present in the body but are not functional. The faster vitamin K1 enters the blood flow, the quicker the coagulation function is restored.
Ruth Vernon, Technical Services Manager for Eurovet said: "We also plan to bring veterinary licenced vitamin K1 tablets to the UK market later in the year, allowing them to be ordered direct from veterinary wholesalers. The future continuity of supply represents a significant improvement on the current situation."
Anticoagulant rodenticide poisoning is the second most common query received by the VPIS. Alexander Campbell, Head of Service at VPIS, said: "The Veterinary Poisons Information Service receives well over 1000 telephone enquiries per annum from UK veterinary professionals seeking advice on how to manage potential and accidental exposures to anticoagulant rodenticides in a variety of animals - mainly pet dogs. Whilst most cases require basic assessment, first-aid and precautionary laboratory tests, an inevitable few develop serious intoxication and need long-term treatment. Vitamin K1 is a mainstay of therapy in these instances, and the availability of licensed veterinary-specific products in the UK is a major advance. Previously, preparations licensed for human use were often the only option when these could be sourced. Anything that ensures ready supply and facilitates speed of therapy for severe cases has to be welcomed."
There are over 500 anticoagulant rodent killing preparations available across Europe. They are available ready to use, as coated cereals, bait blocks, tracking powders, semolina formats or concentrates (which are reserved for professional use). Following cut backs in local council spending on pest control, the National Pest Technicians Association identified in a recent survey* that there is a 'worrying increase in poorly-managed DIY rodent control'.
*The NPTA National Rodent Survey 2009/2010
The ideal Christmas present for a vet to give a child has just landed on my desk.
It's the Amazing ABC Adventure by Lorna Maxwell, out now in paperback from Long Barn Books and available on Amazon here.
Each letter of the alphabet begins an eclectic list of things to be found within a delightful illustration on the facing page. There's a strong animal theme throughout the book: everything from annoyed armadillos and affectionate alligators to worried wombats and yodelling yaks.
One of those books that it's a pleasure to read a child before bed. A steal at £5.79.
Intervet/Schering-Plough Animal Health has launched a new oxytetracycline spray which the company says offers more accurate antibiotic delivery whether the can is used in an upright or inverted position.
Alasdair King MRCVS, Intervet/Schering-Plough Animal Health veterinary manager, says new Engemycin Spray has been developed specifically to address problems reported with traditional aerosol cans:
"Antibiotic sprays are used widely, yet they can become a practical nuisance to both vets and farmers simply because many cans do not perform satisfactorily. All too frequently the nozzle leaks or detaches, the spray pattern is irregular - particularly if the can is held upside down as it so often needs to be - or the valve clogs before the can is empty. This can be a source of great frustration to users, but new Engemycin Spray overcomes all these problems."
Intervet/Schering Plough says Engemycin Spray combines a unique, quick-drying formulation with an innovative, non-clogging spray valve. The quick-drying formulation minimises wastage from the sprayed area, while the new valve - which works as well when the can is upside down - cuts spraying time and ensures more reliable and constant delivery of antibiotic. The valve is unique and designed to enable the can to fully empty.
Engemycin Spray is licensed for the treatment of foot and wound infections in cattle, sheep or pigs following surgery or physical injury. The new product is available now from wholesalers.
The manufacturer has identified that there is a potential for decreased levels of the preservative Chlorobutanol hemihydrate in the following batch: J2101-03 Expiry 11/2018.
Oxytobel is distributed in the UK by Bimeda UK. Veterinary practices that have purchased this batch number should contact Bimeda to arrange collection.
Any queries in relation to return of the product or credit for the product returned should be addressed to Kay Cowton, Bimeda UK Sales on 01248 725400 or email: uksales@bimeda.com
For further information on the recall please contact Bela-pharm GmbH & Co.KG: +49 (0) 44 41 873 294.
In a European first, Pfizer Animal Health is conducting a major study in over 2000 dogs with Trocoxil, its new NSAID which delivers continuous analgesia for a month.
According to the company, Trocoxil has already been granted a licence by the EMEA and pre-authorization studies have already shown once-monthly Trocoxil to be at least as safe and effective as daily carprofen. However, the monthly dosing regimen represents such a big step from the currently used approach of daily NSAID dosing, that Pfizer has decided to initiate the study before launching the product in order to closely monitor and manage the introduction of Trocoxil to the veterinary market.
Jolian Howell, Associate Director Companion Animal Marketing for Pfizer said: "A drug with such a unique dosing regimen should be introduced in a controlled and managed way, and this study is part of that commitment by Pfizer Animal Health."
This large post-approval study, conducted under veterinary control as a User Experience Study, will enable a similar comparison with carprofen to be made in a much larger patient population. In fact it will be sufficiently large to provide product-specific safety information, such as any differences in the incidence of side-effects.
The randomised, parallel group study is being conducted in more than 100 veterinary clinics throughout France, Germany and the UK. Each dog will receive up to 6 months of treatment during which time it will be assessed every month by the veterinary surgeon.
Trocoxil, a preferential COX-2 inhibitor, has a unique pharmacological profile which means that a single oral dose provides continuous pain relief for a whole month.
Jolian added: "This study will provide veterinary surgeons with an opportunity to experience the benefits of using Trocoxil to treat OA continuously over a period of months. It will also give them the opportunity to assess the benefits this offers the owner."
Asked why the CMA had decided to launch the review, its Senior Director for Consumer Protection told BBC R4's Today programme this morning that: "the costs of many vet services are rising higher than the cost of inflation, and it can be really hard to find out how much it's going to cost you, both for routine treatments or if something goes wrong and you need to find emergency care for your pet."
George added: "There's many other [veterinary] services and costs that people cannot have predicted and they can find themselves unexpectedly facing some really high bills, and when other household bills are going up very steeply at the moment we want to do everything we can to make sure that people can predict how much it is going to cost to see a vet, both for routine stuff but also for things if there's a crisis."
The authority is also looking at whether there is enough transparency over practice ownership.
With the percentage of independent practices falling from 89% in 2013 to 45% by 2021, the authority says people may not be clear if their vet is part of a group which owns other vet practices in their area or that the services which are being sold to them (such as diagnostic tests or treatments at a specialist animal hospital) are provided by that group.
This, it says, could impact pet owners’ choices and reduce the incentives of local vet practices to compete.
The CMA is now asking veterinary professionals, people who supply veterinary products and services and pet owners to take part in the review by completing an online questionnaire: https://www.gov.uk/guidance/how-to-respond-to-the-veterinary-services-market-for-pets-review
In particular, it wants to hear practitioners' experiences of:
The questionnaire will remain open for six weeks.
The CMA will outline the issues it identifies and announce its next steps early in 2024.
Elanco Companion Animal Health has launched a competition to encourage veterinary professionals to showcase the company's new range of practice support materials for the company's parasiticides, Comfortis and Trifexin.
To enter the competition, you'll first need to order the support materials, which include: waiting room posters, client leaflets and a waiting room leaflet dispenser, modular window hangers, social media artwork and display kits which consist of 19 die-cut colour pieces for waiting room displays. Entry / order forms are available here.
Then create your display and email a digital photograph of it to Elanco before the 29th August 2014.
Matthew Rowe, Senior Brand Manager at Elanco said: "We're asking veterinary practices to use their creativity and imagination when putting up their parasite control displays. Last year's winner, the Animal Health Centre in Torquay, even composed their own song, so the more creative the better!"
The overall winner will win a team celebration worth £1000, and there are £250 Amazon vouchers for 11 regional winners.
For further information contact your local Elanco Companion Animal Health key account manager or email elancocahuk@elanco.com
The vaccine has been developed from Suvaxyn Circo+MH RTU, and also contains MetaStim as adjuvant 1.
MetaStim is an emulsion containing a metabolisable (non-mineral) oil and is used in vaccines to help elicit both humoral and a cell-mediated immune responses. Zoetis says it is thought to preserve the vaccine components so the antigens are released slowly as compared to other types of adjuvants2.
Alvaro Aldaz, Director Commercial Development and Innovation, Swine, Zoetis, said: "The safety and efficacy of MetaStim has been well documented given its use in several swine, cattle and equine vaccines for the past several years.
"In fact, the MetaStim adjuvant is currently used in our bivalent vaccine – Suvaxyn Circo+MH RTU. Suvaxyn Circo is the monovalent PCV2 fraction of the parent vaccine and it delivers a similar performance profile for PCV2 protection."
More than 250 million pigs are vaccinated against Circovirus every year in Europe.
Professor Hans Nauwynck, Director of the Laboratory of Virology at Ghent University said: "Vaccination of piglets against Circovirus has become a standard in pig farms across Europe.
"The goal is achieving strong immunity, both cell mediated and antibodies, against a virus that is always in the farm.
"Veterinarians should consider several factors when deciding the best timing for vaccination, being especially important the levels of maternal immunity in the pigs to be vaccinated, the presence of co-infections like PRRSV and the expected infection pattern in the farm."
Suvaxyn Circo is a new tool for veterinarians and producers who prefer monovalent vaccines. In situations where early vaccination of piglets against M.hyo is preferred, for example using Suvaxyn MH-One which is licensed for administration from one week of age, there will be a need to give a separate monovalent vaccine to cover PCV2. In such cases, Suvaxyn Circo from three weeks of age can be considered as an option.
Suvaxyn Circo is available in 50- and 125-dose vials.
For more information, contact your Zoetis representative.
The researchers say that ultimately the study should help with the development of guidelines to help all riders assess if they are the right weight for the horse or pony they intend to ride, to enhance both equine welfare and rider comfort and enjoyment.1
Dr Sue Dyson, Head of Clinical Orthopaedics at the Animal Health Trust’s Centre for Equine Studies, Newmarket, who led the study said: "While all the horses finished the study moving as well as when they started, the results showed a substantial temporary effect of rider weight as a proportion of horse weight.
"The results do not mean that heavy riders should not ride but suggest that if they do they should ride a horse of appropriate size and fitness, with a saddle that is correctly fitted for both horse and rider.
"We must remember that this is a pilot study: further work is required to determine if horse fitness, adaptation to heavier weights and more ideal saddle fit will increase the weight an individual horse can carry. This should help us further in our quest to develop guidelines for optimum rider: horse bodyweight ratios."
As the average weight and height of humans continues to increase there is growing debate about relative rider-horse sizes, with riding school horses epitomising the variety of weights of rider that a single horse may be exposed to.
Numerous inter-related aspects are involved with the horse and rider combination including the age of the horse, its fitness and muscle development, the length of its back and the presence or absence of lameness. The rider’s skill, fitness, balance and coordination are important factors, as is the fit of the saddle to both the horse and rider. The type, speed and duration of work and the terrain over which the horse is ridden must also be considered.2
To date little research has been conducted on the effects of rider weight on equine welfare and performance. To address the shortfall World Horse Welfare, the Saddle Research Trust, the British Equestrian Federation and a number of other organisations helped to fund a pilot study last summer, the results of which have now been analysed.
The influence of rider to horse bodyweight ratios on equine gait and behaviour: a pilot study1 assessed gait and behavioural responses in six horses ridden by four riders of similar ability but different sizes. The riders were all weighed in their riding kit and were subsequently categorised as being light, moderate, heavy and very heavy. Their body mass index (BMI) was also calculated.
Each rider rode each horse in its usual tack and performed a set pattern of exercises comprising mainly trot and canter. Gait, horse behaviour, forces under the saddle, the response to palpation of the back, alterations in back dimensions in response to exercise, heart and respiratory rates, salivary cortisol levels and blink rate were assessed for each combination.
The riding tests for the heavy and very heavy riders were all abandoned, predominantly because of temporary horse lameness. This was likely to have been induced by bodyweight rather than BMI, given that the heavy and moderate riders had similar BMIs, both being classified as overweight, yet only one of the moderate rider’s tests had to be abandoned. An ethogram, developed by Dr Dyson specifically to assess behavioural markers which may reflect pain in ridden horses3, was applied. The scores which may reflect pain were significantly higher in the horses when ridden by the heavy and very heavy riders.
The study also raised the issue of rider height and saddle fit. The owner of one of the test horses had a similar bodyweight: horse bodyweight ratio to the heavy rider and was of similar weight, but significantly different in height (157.0 and 185.5 cm, respectively). This large difference in height has major potential implications for saddle fit for the rider and consequently the rider’s position and weight distribution. The taller rider sat on the back of the cantle, overloading the back of the saddle and making it more difficult to ride in balance, with the heel being in front of a vertical line between the shoulder and ‘hip’.
Roly Owers, Chief Executive of World Horse Welfare, said: "These pilot results are certainly not surprising but are very significant in adding vital evidence to inform an appropriate rider: horse weight ratio. It is common sense that rider weight impacts equine welfare however many might not fully understand or recognise this. What is desperately needed is basic guidance to help riders identify a horse or pony that is right for them and this research is a vital step in that direction.”
The study was generously supported by World Horse Welfare, the Saddle Research Trust, Frank Dyson, British Equestrian Federation, British Horse Society, Pony Club, Polocross, The Showing Council, The Showing Register, The Society of Master Saddlers, Riding for the Disabled, British Eventing, British Dressage, the British Horse Foundation, the Worshipful Company of Saddlers and Endurance GB.
Billed as an essential reference, the new guide gives practical information on pain management in a wide range of small animals, emphasizing patient welfare and evidence-based medicine.
The BSAVA Guide to Pain Management in Small Animal Practice is edited by Ian Self, an RCVS and European Specialist in Veterinary Anaesthesia and Analgesia.
Each chapter is written by a specialist in the field, and the guide includes 'Authors’ perspectives' and case examples.
The first six chapters cover key areas in pain management, including the physiology of pain, acute and chronic pain, and pharmacological and physical treatment of pain. The remaining chapters look at specific types of pain, and pain in species commonly encountered in small animal practice.
Ian said: "This Guide is not to be seen as an instruction manual, rather a helping hand. For each case discussed and analgesic approach explained, there are multiple valid alternative approaches… when seeking inspiration or information when faced with a patient in pain, we hope that the information presented here will assist in reaching a satisfactory clinical outcome."
The new book will be given to eligible vet and vet nurse members free of charge as part of the Association's loyalty scheme; a 'thank you' for staying a member for another year. Further details are available from the member benefits section of the BSAVA website.
Alstoe is launching Vetergesic Multidose, a 10ml version of the opiate injection, in a new multi-use vial.
Alstoe Technical Director, Dr Ian Ryder said: "In addition to the new vial size the inclusion of a preservative enables Vetergesic Multidose to be used for up to 28 days following its initial use. Also the product is now licensed for intravenous administration."
Vetergesic Multidose should drastically reduce the amount of product wasted by practices using the old, smaller single-use vial.
Alstoe says that supplying Vetergesic in a multi-use vial was one of the first things discussed with the drug originators, Reckitt Benckiser, when it took over the marketing of the product. However, for a large scale medical pharmaceutical manufacturer to consider producing a veterinary product in a different pack and in much smaller production runs than their medical operating scales, the answer is normally no. But in this case, Reckitts gave the project its full support, so in addition to reduced wastage, the inconvenience of snapping glass necks will become a thing of the past.
Please contact Alstoe Ltd for further information at info@alstoe.co.uk or telephone 01347 878606.
The pads contain ophytrium and chlorhexidine at 3%. Ophytrium is a purified natural ingredient from Ophiopogon japonicus which, Ceva says, strengthens the mechanical skin barrier1, restores the balance of protective microbial flora2 and reduces irritation, while soothing the skin1. Chlorhexidine is both antibacterial and antifungal.
Ceva says that Douxo S3 Pyo pads, which come in packs of 30, provide antibacterial and antifungal efficacy within one minute and are free from soap, parabens, sulphates, phthalates, colourants and nanoparticles.
They are available in a new, hypoallergenic ‘summertime’ fragrance which pet owners liken to coconut and vanilla.
The pads add to the Douxo S3 Pyo range, which also consists of shampoo and a mousse.
Andrew Fullerton BVSc (Hons) MRCVS, product manager for Douxo S3 at Ceva said: "The new Douxo S3 range has been well received by both veterinary professionals and their clients since its launch, who find that the products are not only effective and well tolerated, but also easy-to-use. The Douxo S3 Pyo pads will enhance this range by offering an easy-to-administer antiseptic action while hydrating and maintaining the skin’s ecosystem.”
For further information, contact cevauk@ceva.com, your local territory manager or visit https://www.douxo.com/uk/Pet-Skin-Care/douxo-s3.
The company warned last year that Equip Artervac would be out of stock from the end of November 2017 until mid-2018, but says that the re-availability of the vaccine means many vaccinated stallions and teasers should now be able to have their six-monthly booster dose within the normal designated timeframe.
Equip Artervac is indicated for the active immunisation for horses against equine arteritis virus to reduce the clinical signs and shedding of virus in nasal secretions following infection.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.